leisure time -WSS

leisure time

author：entertainment 2025-09-30 08:49:33 - browse：251

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： FDA seeks to regulate lab

hotspot

knowledge

WSS

Zapping the brain for stroke rehab: Pivotal clinical trial begins

FDA advisers vote against ALS treatment from BrainStorm

FTX founder Sam Bankman

Address the ethical violations that led to 'Three Identical Strangers'

Sudafed saga points to U.S. issues with evaluating older drugs

Sage's campaign to raise awareness of postpartum depression hits a nerve

explore

leisure time

focus

Moonlake's readout produced a cash windfall. Risks remain

Inequities make cancer less preventable for women: report

Duchenne breakthrough therapy leaves behind pioneering families

Covid vaccines: Private market messier than government rollout

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Novavax promises a turnaround & Lilly roils the obesity market

Biogen shutters digital health group, ends Apple study, in cost cutting move

BioMarin wins approval for gene therapy to treat hemophilia A

Inequities make cancer less preventable for women: report

hotspot

Biogen shutters digital health group, ends Apple study, in cost cutting move

Researchers use wearables data and AI to predict preterm birth risk

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Researchers use wearables data and AI to predict preterm birth risk

Ohioans vote in high

An Ebola outbreak presents a new mystery involving children

focus

hotspot

knowledge

hotspot